Literature DB >> 1260710

Immunochemotherapy in human lung cancer using the streptococcal agent OK-432.

I Kimura, T Ohnoshi, S Yasuhara, M Sugiyama, Y Urabe.   

Abstract

Streptococcal agent OK-432 was administered at maintenance levels with conventional inductive chemotherapeutic agents to stage III and IV lung cancer patients. Survival rates were longer in patients treated with OK-432 than in patients treated without OK-432. An enhancement of lymphocyte blastogenic activity and a delayed PPD skin reaction were found in patients treated by OK-432. A low grade fever was present as a side effect of this agent in some patients. The results suggest that OTK-432 may be useful immunotherapeutic agent in combination with induction chemotherapy in reducing host damage in advanced stages of lung cancer.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 1260710     DOI： 10.1002/1097-0142(197605)37:5<2201::aid-cncr2820370507>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


  6 in total

1.  Immunologic parameters in patients with thyroid cancer.

Authors:  K Makimoto; M Ohmura; T Hoshino
Journal:  Arch Otorhinolaryngol       Date:  1986

2.  Augmentation of natural killer (NK) cell activity by a streptococcal preparation, OK-432, in patients with malignant tumors.

Authors:  H Wakasugi; K Oshimi; M Miyata; Y Morioka
Journal:  J Clin Immunol       Date:  1981-07       Impact factor: 8.317

3.  Efficacy of streptococcal preparation OK-432 for gastric cancer patients--comparison between intradermal and intramuscular injection.

Authors:  H Hanaue; T Kurosawa; S Yoshizaki; J Shikata
Journal:  Jpn J Surg       Date:  1984-05

4.  Immunological responsiveness and adjunct immunotherapy in lung cancer.

Authors:  M Fukushima; S Machida; H Kakuta; T Nishikawa; A Kikuchi; K Takashima; T Ishioka; Y Ishikawa
Journal:  Jpn J Surg       Date:  1978-12

5.  OK432 inhibits experimental hepatic metastasis of colon adenocarcinoma ACL-15 in F344 rats.

Authors:  F Sugimoto; K Tsukada; K Hatakeyama; K Yoshida; T Muto
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

6.  Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion.

Authors:  Y Nio; H Nagami; K Tamura; M Tsubono; M Nio; M Sato; K Kawabata; H Hayashi; T Shiraishi; S Imai; T Tsuchitani; J Mizuta; M Nakagawa; M Fukumoto
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.